{"filings":[{"id":96031,"accession_number":"0001193125-26-211935","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.","Cash of $117.2M as of March 31; April private placement raised $30M, extending runway into Q1 2028.","Phase 2b ADAPTIVE trial in AD advancing under amended protocol; topline data anticipated Q4 2027.","Plan to initiate Phase 2 in alopecia areata in 2026; initial data expected 2028, based on proof-of-concept."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96030,"accession_number":"0001193125-26-151942","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ImageneBio raises ~$30M via pre-funded warrants to fund atopic dermatitis and alopecia areata programs","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$30M from sale of pre-funded warrants for 5.77M shares at $5.199 each.","Closing expected April 14, 2026; warrants exercisable at $0.001, no expiration.","Proceeds to fund late-phase development in atopic dermatitis and expand IMG-007 into alopecia areata.","Registration rights agreement requires filing by early August 2026; cash penalties for delays.","Beneficial ownership limitation set at 19.99% per investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109528,"accession_number":"0001193125-26-110945","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ImageneBio PAO Erin Butler to depart; Bob Lally named as successor","event_type":"leadership","confidence":"high","bullets":["Mutual separation of Erin Butler, SVP Finance & Administration and Principal Accounting Officer, effective March 20, 2026.","Bob Lally, SVP Finance & Operations, appointed as Principal Accounting Officer effective March 20, 2026.","Butler to receive severance per existing Severance Rights Agreement dated October 21, 2024.","Lally previously served at Ikena Oncology (SVP Finance & Operations) and Prevail Therapeutics (VP Finance, COO)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109527,"accession_number":"0001193125-26-099422","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImageneBio reports Q4 2025 net loss $6.9M; cash $135.3M; Phase 2b ADAPTIVE on track for 2027","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents and marketable securities: $135.3M at Dec 31, 2025 vs $12.1M at Dec 31, 2024, after merger and $75M private placement.","Net loss Q4 2025: $6.9M vs $4.8M Q4 2024, driven by post-merger operating costs and transaction expenses.","Phase 2b ADAPTIVE trial (IMG-007 in atopic dermatitis) enrolling on schedule; blinded safety review found no pyrexia/chills/ulcers/malignancies.","Appointed Dr. Ben Porter-Brown as CMO in Feb 2026; also added CEO, CSO, CTO, and an independent director during 2025.","Submitted protocol amendment to expand dosing regimens, evaluate loading doses, and test patient-friendly intervals in ADAPTIVE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109526,"accession_number":"0001193125-26-054684","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ImageneBio board member Steven Hui Wang resigns effective Feb 12, 2026","event_type":"leadership","confidence":"high","bullets":["Steven Hui Wang resigned from the Board of Directors on February 12, 2026, effective immediately.","Resignation was not due to any disagreement with the Company's operations, policies, or strategy.","No replacement has been announced; board size reduces accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126055,"accession_number":"0001193125-25-324798","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Imagenebio CMO Yufang Lu resigns effective Dec 31, 2025; search underway","event_type":"leadership","confidence":"high","bullets":["Yufang Lu, M.D., Ph.D., Chief Medical Officer, resigned effective December 31, 2025.","Resignation not due to any disagreement with company operations, policies, or practices.","Company conducting search for replacement; Lu expected to provide transition advisory services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126054,"accession_number":"0001193125-25-286984","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ImageneBio updates corporate presentation; no new material details disclosed","event_type":"other_material","confidence":"low","bullets":["Company released updated corporate presentation dated November 19, 2025.","Presentation posted on company website for investor meetings.","No financial or operational updates were provided in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126053,"accession_number":"0001193125-25-275910","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImageneBio reports Q3 net loss of $24.8M; advances Phase 2b AD trial with protocol amendment","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $142.6M as of Sep 30, 2025; net loss $24.8M for Q3 2025 vs $3.2M in Q3 2024; R&D $15.6M, G&A $11.0M.","Phase 2b ADAPTIVE trial protocol amendment to expand dosing regimens; topline data expected in 2027; enrollment ongoing.","New alopecia areata data (Phase 1b/2a) and atopic dermatitis data to be presented at ISDS Nov 12-15, 2025.","Completed reverse merger with Ikena Oncology and $75M private placement; new CEO Kristin Yarema, CSO Kurinji Pandiyan, CTO Renuka Sivendran, and independent director Joe Slattery."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":800000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126052,"accession_number":"0001193125-25-266889","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ImageneBio appoints Joseph P. Slattery to Board and Audit Committee chair","event_type":"leadership","confidence":"high","bullets":["Board size increased from 6 to 7; Slattery appointed director effective Nov 1, 2025.","Slattery to serve as Audit Committee Chair effective Nov 18, 2025.","Standard indemnification agreement entered into with Slattery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126051,"accession_number":"0001193125-25-254697","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Imagenebio terminates Miragene transition agreement; extends partial services for 6 months at $200K","event_type":"other","confidence":"high","bullets":["Elected not to auto-renew transition services agreement with Miragene Inc. dated July 25, 2025.","Extended term six months for subset of services (chemistry, manufacturing, controls, translational sciences).","Total fees for Miragene Extension Services: $200,000.","End of initial term triggers partial extension; full termination after extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126050,"accession_number":"0001193125-25-245823","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ImageneBio CEO Kristin Yarema appointed interim principal financial officer","event_type":"leadership","confidence":"high","bullets":["Board appointed CEO Kristin Yarema as interim CFO effective Oct 21, 2025.","Yarema previously served as CEO; biographical info referenced from Sept 2025 S-1 filing.","No reason for the change or prior CFO departure disclosed in the filing.","The appointment is effective immediately; Yarema continues as CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126049,"accession_number":"0001193125-25-237161","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Jotin Marango resigns effective Oct 20; search for replacement begun","event_type":"leadership","confidence":"high","bullets":["CFO Jotin Marango, M.D., Ph.D., resigned effective October 20, 2025.","Resignation not due to any disagreement with the company.","Company will conduct a search for Marango's replacement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142782,"accession_number":"0001193125-25-179093","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K/A","filed_at":"2025-08-12T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"ImageneBio files Inmagene pre-merger financials: $13.7M loss, going concern, $6M cash","event_type":"other_material","confidence":"high","bullets":["Inmagene net loss of $7.6M in Q2 2025 and $13.7M in first half 2025; accumulated deficit $197.5M.","Cash and equivalents $6.0M at June 30, 2025; operating cash burn $19.1M in first half 2025.","Management states substantial doubt about continuing as a going concern; cash insufficient for next 12 months.","Term loan of $22.9M (6% interest, secured by IMG-007) automatically forgiven upon merger close July 25, 2025.","Ikena concurrent financing of $75M contributed to fund IMG-007 development after merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142785,"accession_number":"0001193125-25-173626","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ImageneBio dismisses EY, appoints PwC as auditor effective Aug 2, 2025","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed Ernst & Young LLP as independent auditor effective August 2, 2025.","No disagreements or reportable events occurred during EY's audit periods (2024, 2023 and interim).","PricewaterhouseCoopers LLP appointed as new auditor for fiscal year ending Dec 31, 2025.","PwC previously served as auditor of Inmagene Biopharmaceuticals prior to merger with ImageneBio.","EY's audit reports for 2024 and 2023 were unqualified, with no adverse opinions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142784,"accession_number":"0001193125-25-171747","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"ImageneBio adopts 2025 Inducement Plan, reserves 589,585 shares for new employee equity grants","event_type":"other_material","confidence":"high","bullets":["Board approved 2025 Inducement Plan on July 28, 2025, reserving 589,585 shares for grants to new employees.","Plan used exclusively for inducement grants to individuals not previously employees or directors, per Nasdaq Listing Rule 5635(c)(4).","Terms substantially similar to stockholder-approved 2025 Equity Incentive Plan; no stockholder approval required.","Award types: Nonstatutory Stock Options and RSUs; vesting and exercise terms standard."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142783,"accession_number":"0001193125-25-167089","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.01","1.01","3.02","9.01","5.02","3.03","5.01","5.03","5.06","7.01"],"status":"ready","headline":"Ikena completes reverse merger with Inmagene, becomes ImageneBio; focuses on IMG-007 for atopic dermatitis","event_type":"m_and_a","confidence":"high","bullets":["Merger closed July 25: Ikena acquired Inmagene, name changed to ImageneBio, ticker changes to IMA on Nasdaq Capital Market.","Reverse stock split 1-for-12; post-merger shares ~11.2M; pre-merger Inmagene holders get ~43.5% of combined co.","Only clinical asset: IMG-007 (anti-OX40 mAb) in Phase 2b ADAPTIVE trial for atopic dermatitis; non-OX40 assets divested.","CVR agreements provide contingent payments to legacy Ikena and Inmagene shareholders from future asset sales.","PIPE investors own ~21.5%; Hutchmed license has up to $92.5M in development/regulatory milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142781,"accession_number":"0001193125-25-165170","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement","event_type":"m_and_a","confidence":"high","bullets":["Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.","Concurrent $75.0M private placement from investors including Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors.","Legacy Inmagene holders own ~55% (pre-financing) or ~43.1% (post-financing); Ikena holders own ~45% (pre) or ~35.3% (post); new investors own ~21.6%.","ImageneBio to advance IMG-007 Phase 2b trial in moderate-to-severe atopic dermatitis; topline readout expected Q4 2026.","Kristin Yarema, Ph.D. appointed CEO; Ikena implemented a 1-for-12 reverse stock split prior to closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142780,"accession_number":"0001193125-25-163990","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ikena Oncology to effect 1-for-12 reverse stock split, rename to ImageneBio, ticker IMA","event_type":"other_material","confidence":"high","bullets":["1-for-12 reverse stock split effective July 28, 2025; shares outstanding drop from ~48.2M to ~4M.","Company will rename ImageneBio, Inc., trade under ticker \"IMA\" on Nasdaq, new CUSIP 45175G207.","No fractional shares; cash paid based on July 24 closing price multiplied by fractional share.","Exercise prices and shares underlying equity awards will be proportionally adjusted; par value unchanged.","Stockholders in book-entry or brokerage accounts need no action; beneficial holders contact broker."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142779,"accession_number":"0001193125-25-162584","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ikena Oncology declares one-time CVR dividend; record date July 24, 2025","event_type":"other_material","confidence":"high","bullets":["Board approved one contingent value right (CVR) per share of IKNA common stock.","Shareholders of record as of July 24, 2025 will receive one CVR per share.","CVRs entitle holders to net proceeds from sales of pre-Merger assets, including IK-595.","Proceeds subject to deductions for taxes, expenses, and wind-down costs.","No assurance any CVR payments will be received; CVRs may have no value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142778,"accession_number":"0001193125-25-159910","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ikena Oncology amends executive’s equity vesting terms tied to pending Inmagene merger","event_type":"leadership","confidence":"high","bullets":["Effective July 15, 2025, Ikena Oncology amended employment agreement with Dr. Jotin Marango, an executive officer.","Amendment provides for full acceleration of time-based equity awards if termination without cause or resignation during change in control period.","Change in control period began March 18, 2025 (initial S-4 filing for merger with Inmagene) and ends 12 months post-merger.","Accelerated vesting effective later of termination date or change in control; forfeiture of unvested portions delayed until that date.","Contemplated merger with Inmagene Biopharmaceutics was announced December 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142777,"accession_number":"0001193125-25-159400","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Ikena stockholders approve Inmagene merger; 1:12 reverse split; combined co. to trade as IMA","event_type":"m_and_a","confidence":"high","bullets":["All 7 proposals approved including merger issuance of IKNA shares >20% and reverse split.","1-for-12 reverse stock split to reduce outstanding shares from ~48.2M to ~4M.","Merger and concurrent financing expected to close around end of July 2025.","Combined company will be ImageneBio, Inc., trading on Nasdaq under ticker IMA.","New CUSIP for post-split common stock: 45175G 207."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142776,"accession_number":"0001193125-25-157867","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ISS and Glass Lewis recommend Ikena stockholders vote FOR Inmagene merger","event_type":"m_and_a","confidence":"high","bullets":["Institutional Shareholder Services (ISS) and Glass Lewis recommend voting FOR share issuance related to merger with Inmagene.","Ikena's Annual Meeting is July 15, 2025; record date was May 22, 2025.","Inmagene's lead candidate is IMG-007, a nondepleting anti-OX40 mAb for immune & inflammatory diseases.","CEO Mark Manfredi cited IMG-007's potential to build shareholder value in I&I space.","Proxy includes seven proposals; all votes are important for merger approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142775,"accession_number":"0001193125-25-154016","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Inmagene doses first patient in Phase 2b ADAPTIVE trial of IMG-007 for atopic dermatitis; data expected Q4 2026","event_type":"other_material","confidence":"high","bullets":["IMG-007 targets OX40 receptor with silenced ADCC to minimize safety risks and extended half-life for convenient dosing.","ADAPTIVE trial is a global Phase 2b enrolling ~220 patients across three IMG-007 dose arms and placebo.","Primary endpoint: mean percentage change from baseline in EASI score at Week 20.","Topline results from the Phase 2b trial are expected in the fourth quarter of 2026.","Dose-finding study designed to guide optimal dosing for future Phase 3 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}